On January 28, 2026, the U.S. Securities and Exchange Commission’s Division of Corporation Finance, Division of Investment Management and Division of Trading and Markets issued a Statement on Tokenized Securities that...more
2/13/2026
/ Blockchain ,
Compliance ,
Digital Assets ,
Distributed Ledger Technology (DLT) ,
New Guidance ,
Regulatory Requirements ,
Securities and Exchange Commission (SEC) ,
Securities Regulation ,
Securities Tokens ,
Security Token Offering (STOs) ,
Tokenization
Publicly sharing clinical results can trigger a range of regulatory and compliance obligations, especially for companies approaching or already in the public markets. As scrutiny on life sciences communications increases,...more
12/23/2025
/ Clinical Trials ,
Corporate Governance ,
Data-Sharing ,
Disclosure Requirements ,
Food and Drug Administration (FDA) ,
Form 8-K ,
Investors ,
Life Sciences ,
Pharmaceutical Industry ,
Public Communications ,
Publicly-Traded Companies ,
Regulatory Requirements ,
Securities and Exchange Commission (SEC)
For any life sciences company, a clinical data readout is more than a scientific milestone. It’s a corporate event that can influence investor sentiment and the broader perception of the program. ...more
The SEC will allow initial public offerings (IPOs) and other transactions that typically rely on the incorporation of pricing information into the registration statement using Rule 430A to become effective during the ongoing...more
The journey to becoming a public company requires strategic planning and thoughtful coordination. While the IPO process typically spans six months or more, laying the groundwork should begin much earlier to ensure a smooth...more
The outlook for life sciences IPOs is showing renewed optimism heading into 2025, with market conditions becoming more constructive and regulatory environments potentially more favorable....more
For publicly traded biotech companies, disclosing clinical trial data can be an exciting milestone as you build towards an exit or public offering—but disclosure is a double-edged sword....more
1/6/2025
/ Capital Raising ,
Clinical Trials ,
Corporate Governance ,
Disclosure Requirements ,
Initial Public Offering (IPO) ,
Investors ,
Life Sciences ,
Material Nonpublic Information ,
Medical Research ,
Pharmaceutical Industry ,
Private Investment in Public Equity (PIPEs) ,
Publicly-Traded Companies
When it comes to disclosing clinical trial data in the biotechnology arena, in particular for public biotech companies, timing is everything. Disclosures are not just about when to reveal the information, but also what is...more
1/6/2025
/ Annual Reports ,
Biotechnology ,
Clinical Trials ,
Corporate Governance ,
Disclosure Requirements ,
Financial Industry Regulatory Authority (FINRA) ,
Food and Drug Administration (FDA) ,
Form 10-K ,
Form 10-Q ,
Life Sciences ,
Pharmaceutical Industry ,
Securities and Exchange Commission (SEC)
Demand for tokenized real-world assets (RWAs) is rapidly growing across the decentralized finance (DeFi) community, with growing interest among existing crypto-native participants and across the traditional finance industry...more
5/10/2024
/ Asset Tokens ,
BlackRock ,
Bonds ,
Corporate Issuers ,
Decentralized Finance (DeFi) ,
Digital Platforms ,
EU ,
Financial Instruments ,
Form S-1 ,
Investment Funds ,
Monetary Authority of Singapore ,
Registration Requirement ,
Registration Statement ,
Regulation A ,
Regulation CF ,
Regulatory Agenda ,
Securities Act of 1933 ,
Securities and Exchange Commission (SEC) ,
Stablecoins ,
Tokenization
Institutional Shareholder Services (ISS) and Glass Lewis, the leading proxy advisors in the United States, have announced updates and clarifications for their voting guidelines for the 2023 proxy season. Their voting...more
12/6/2022
/ Board of Directors ,
Climate Change ,
Cybersecurity ,
Disclosure Requirements ,
Diversity and Inclusion Standards (D&I) ,
Environmental Social & Governance (ESG) ,
Glass Lewis ,
Institutional Shareholder Services (ISS) ,
Overboarding ,
Proxy Advisors ,
Proxy Voting Guidelines ,
Publicly-Traded Companies ,
Securities and Exchange Commission (SEC) ,
Shareholders ,
Voting Rights
As biotech markets begin to show signs of life, how should company leaders and investors prepare for what’s next?
Biotech executives, investment bankers and partners from Deloitte’s life sciences practice and Fenwick’s...more
On February 25, 2022, the U.S. Securities and Exchange Commission issued a proposal—Short Position and Short Activity Reporting by Institutional Investment Managers (the Proposal)—that would require certain institutional...more
3/4/2022
/ Broker-Dealer ,
Consolidated Audit Trail ,
Disclosure Requirements ,
Investment Adviser ,
Proposed Amendments ,
Proposed Rules ,
Publicly-Traded Companies ,
Regulation SHO ,
Securities and Exchange Commission (SEC) ,
Securities Exchange Act of 1934 ,
Stocks
Gary Gensler, the new chairman of the U.S. Securities and Exchange Commission, released a statement on June 1, 2021, directing SEC staff to consider revisiting its interpretation and guidance from September 2019 regarding the...more
Glass Lewis announced updates to its United States Proxy Voting Policy Guidelines late November 2020. The 2021 Proxy Voting Policy Guidelines include a variety of changes from the 2020 version, including new provisions...more
12/10/2020
/ Board of Directors ,
Coronavirus/COVID-19 ,
Corporate Governance ,
Disclosure ,
Diversity ,
Glass Lewis ,
Golden Parachutes ,
Initial Public Offering (IPO) ,
Institutional Shareholder Services (ISS) ,
Investors ,
Proxy Season ,
Proxy Voting Guidelines ,
Publicly-Traded Companies ,
Say-on-Pay ,
Securities and Exchange Commission (SEC) ,
Special Purpose Acquisition Companies (SPACs) ,
State and Local Government ,
Virtual Meetings
Institutional Shareholder Services (ISS) announced benchmark voting policy changes in the United States, increasing expectations for board racial and ethnic diversity, adding director accountability for environmental and...more
The U.S. Securities and Exchange Commission on July 22, 2020, adopted amendments tightening regulation of proxy voting advice from proxy advisory firms (Release No. 34-89372). The final rule implements additional regulations...more
7/28/2020
/ Conflicts of Interest ,
Disclosure ,
Filing Requirements ,
New Amendments ,
New Guidance ,
Proxy Advisors ,
Proxy Advisory Firms ,
Proxy Solicitations ,
Proxy Voting Guidelines ,
Regulatory Oversight ,
Securities and Exchange Commission (SEC)
The U.S. Securities and Exchange Commission has proposed amendments to the proxy solicitation rules, directly targeting proxy advisory firms (Release No. 34-87457). Consistent with the updated interpretative guidance the SEC...more
11/19/2019
/ Conflicts of Interest ,
Disclosure Requirements ,
Exemptions ,
Filing Requirements ,
Investment Adviser ,
Proposed Rules ,
Proxy Advisors ,
Proxy Advisory Firms ,
Proxy Season ,
Proxy Solicitations ,
Proxy Statements ,
Proxy Voting ,
Proxy Voting Guidelines ,
Public Comment ,
Securities and Exchange Commission (SEC) ,
Shareholder Meetings